BLIS Technologies (BLT) H1 2026 earnings summary

Executive summary

• Achieved revenue of $7.7m for the six months to 30 September 2025, a 28% increase year-over-year, with strong growth in both B2B and B2C channels.

• EBITDA reached $0.5m, up $0.2m year-over-year, with underlying EBITDA at $1.3m, excluding a $0.8m one-off supply chain cost increase.

• Ingredient orders, private label growth, and improved execution in key markets drove performance.

• Marked 25th anniversary with a celebration and leadership transition, as Dame Alison Stewart became Chair.

Financial highlights

• B2B revenue was $5.3m (68% of total), up 39% year-over-year, led by EMEA growth of 83%.

• B2C revenue was $2.4m, up 10% year-over-year, with strong performance in New Zealand wholesale and Amazon channels.

• Private-label revenue surged 204% to $0.8m; royalty revenue up 25% to $0.5m.

• Net surplus for the period was $419k, up from $229k in the prior year.

• Cash and cash equivalents at period end were $3.0m, down from $3.5m at the prior period end.

Outlook and guidance

• Full year FY26 revenue growth expected between 10%-15% over FY25.

• Focus on accelerating Probi's oral probiotics launches in EMEA and North America, including pet nutrition, supporting China regulatory milestones, and expanding product development.

• Positioned for steady, profitable growth leveraging science leadership and international partnerships.